INTRODUCTION:
The major objective of oral controlled drug delivery system is todeliver drugs for longer period of time to achieve betterbioavailability, wh ich should be predictable and reproducible.But this is difficult due to number of physiological problems such as fluctuation in the gastric emptying process, narrowabsorption window and stability problem in the intestine. An Ideal drug delivery system should possess two main properties:
(1) It should be a single dose for the whole duration of the treatment.
(2) It should deliver the active drug directly at the site of action 1 . Gastroretentive drug delivery system (GRDDS) is one of the novel approach in this area.Oral controlled release dosage forms are the mostcommonly formu lated but still offer highest attentionin the area of novel drug delivery systems 2 . Drugs that areeasily absorbed from gastrointestinal tract (GIT) and have short half-lives are eliminated quickly fro m the systemic circu lation. Frequent dosingof these drugs is required to achieve suitabletherapeutic activity. To avoid this limitation,the development of oral sustained-controlledrelease formulat ions is an attempt to release thedrug slowly into the GIT and maintain an effective drug concentration inthe systemic circulat ion for a long time. Afteroral administration, such a drug delivery wouldbe retained in the stomach and release the drugin a controlled manner, so that the drug could besupplied continuously to its absorption sites in the GIT. 3 Poor absorption of many drugs in the lower GIT necessitates controlled release dosage forms to be maintained in the upper GI tract, particularly the stomach and upper small intestine. 4 These drugdelivery systems suffer fro m main ly twoadversities: the short gastric retention time(GRT) and unpredictable short gastric emptyingtime (GET), which can result in inco mplete drugrelease from the dosage form in the absorptionzon e (stomach or upper part of small intestine)leading to dimin ished efficacy of ad ministered dose. 5 To formulate a site-specific orallyad min istered controlled release dosage form, itis desirable to achieve a prolong gastricresidence time by the drug delivery. GRDDS are thus beneficial for such drugs by imp roving their bioavailability, therapeutics efficacy and possible reduction of the dose and improves the drug solubility that is less soluble in a high pH environment. 6 Apart of these advantages, these systems offer various pharmacokinetics advantages like maintenance of constant therapeutic levels over a prolonged period and thus reduction in fluctuation in the therapeutic levels. 7 Gastric retention will provide advantages such as the delivery of drugs with narrow absorption windows in the s mall intestinal reg ion. Also prolonged gastric retention time in the stomach could be advantageous for localaction in the upper part of the small intestine. The stomach is an organ with a capacity for storage and mixing. Anatomically the stomach is divided into three regions: Fundus, Body and antrum (pylorus). The pro ximal part made up of fundus and body which acts as a reservoir for undigested material, whereas the antrum is the main site for mixing motions and act as a pump for gastric emptying by propelling actions. 8 Under fasting conditions, the stomach is a collapsed bag with a residual volume of approximately 50ml and contains a small amount of gastric flu id (pH 1-3) and air. The mucus spreads and covers the mucosal surface of the stomach as well as the rest of the GI tract. The GI tract is in a state of continuous motility consisting of two modes, interdigestive motility pattern and digestive motility pattern. The former is dominant in the fasted state with a primary function of clean ing up the residual content of the upper GIT. The interdigestive motility pattern is commonly called the "migrat ing motor complex" ("MM C") and is organised in cycles of activity and quiescence. 9
PHYS IOLOGY OF STOMACH:

NEEDS FOR GAS TRO RETENTION 11
·Drugs that are absorbed fro m the pro ximal part of the gastrointestinal tract (GIT).
·Drugs that are less soluble or are degraded by the alkaline pH they encounters at the lower part of GIT.
·Drugs that are absorbed due to variable gastric emptying time. ·Local or sustained drug delivery to the stomach and proximal Small intestine to treat certain conditions. ·Part icularly useful for the treatment of peptic ulcers caused by H. Pylo ri Infections. 12 1. Drugs that have very limited acid solubility. e.g. phenytoin etc. 2.Drugs that suffer instability in the gastric environ ment. e.g. erythromycin etc. 3.Drugs intended for selective release in the colon. e.g. 5amino salicylic acid and corticosteroids etc.
IDEAL DRUG CHARACTERIS TICS FOR GRDDS
UNS UITAB LE DRUGS FOR GRDDS
FACTORS CONTROLLING GRDDS
The stomach anatomy and physiology contain parameters to be considered in the development of gastroretentive dosage forms. To pass through the pyloric valve in to the small intestine the particle size should be in the range of 1 to 2 mm. 13 The most important parameters controlling the GRT of oral dosage forms include : density, size, shape of the dosage form, food intake and its nature, caloric content, frequency of intake, posture, gender, age, sex, sleep, body mass index, physical activ ity, diseased states of the individual ( e.g. chronic disease, diabetes etc.) and administration of drugs with impact on GI transit time.for example drugs acting as anticholinergic agents ( e.g. atropine, propantheline), Opiates ( e.g. codeine) and prokinetic agents ( e.g. metclopramide, cisapride.) 14 . The mo lecular weight and lipophilicity of the drug depending on its ionizat ion state are also important parameters. 15
A. Dosage form related factors
Density of dosage forms: Dosage forms having a density lower than the gastric contents can float to the surface, while high density systems sink to bottom of the stomach. 16 Both positions may isolate the dosage system fro m the pylorus. A density of < 1.0 g m/ cm3 is required to exhibit floating property. 17 However; the floating tendency of the dosage form usually decreases as a function of time, as the dosage form gets immersed into the fluid, as a result of the development of hydrodynamic equilibriu m. 18
Size of the dosage form:
The mean GRT of nonfloating dosage forms are highly variable and greatly dependent on their size, wh ich may be large, mediu m and small units. 19 In most cases, the larger the dosage form the greater will be the GRT due to the larger size of the dosage form would not allow this to quickly pass through the pyloric antrum into the intestine 20 . Dosage forms having a diameter of more than 7.5 mm show a better gastric residence time co mpared with one having 9.9 mm 17 . Thus the size of the dosage form appearsto be an important factor affecting gastric retention. 20 © 2011, JDDT. All Rights Reserved ISSN: 2250 -1177 CODEN: JDDTAO Shape of the dosage form: Ring-shaped and tetrahedronshaped devices have a better gastric residence time as compared with other shapes 21 .
Single or multi ple unit formul ation: Mu ltiple unit formulat ions show a more predictable releaseprofile and insignificant impairing of performancedue to failu re of units, allow co-ad min istration ofunits with different release profiles or containingincompatible substances and permit a largermargin of safety against dosage form failureco mpared with single unit dosage forms.
B. Food intake and its nature
Thepresence or absence of food in the GIT influences the GRT of the dosage form.Usually the presence offood in the GIT imp roves the GRT of the dosage form andthus, the drugs absorption increases by allowing itsstay at the absorption site for a longer period.Again, increase in acidity and caloric value showsdown gastric emptying time and improve the gastric retention of dosage forms 22 . Food habits affect the GRT in the fo llo wing ways 23 .
Fed or unfed stateunder fasting conditions, theGI motility is characterized byperiods of the migrat ingmyoelectric comp lex (MM C) that occursevery 1.5 to 2 hours. The MMC sweeps undigestedmaterial fro m the stomach and, if thetiming of ad min istration of the formulat ioncoincides with that of the MMC, the GRT of theunit can be expected to be very short. However, inthe fed state, MMC is delayed and GRT isconsiderably longer. It was concluded that as mealswere given at the time when the previous digestivephase had not completed, the floating form buoyantin the stomach could retain its position for anotherdigestive phase as it was carried by the peristalticwaves in the upper part of the stomach.
Nature of mealfeeding of indigestible poly mersor fatty acid salts can change themotility pattern of the stomach to a fed state, thusdecreasing the gastric emptying rate andprolonging drug release.
Cal oric content -GRT can be increased by four to10 hours with a meal that is high inproteins and fats.
Frequency of feedthe GRT can increase by over400 minutes when successive mealsare g iven compared with a single meal due to thelow frequency of MMC.
C. Patient related factors
Gender : Generally femalesshowed comparatively shorter mean a mbulatory GRT than males, and the gastric emptying in wo men was slower than in men. 24
Age: In case of elder persons, gastric emptying is slowed down, especially those over 70, have a significantly longer GRT;
Posture: GRT can vary between supine and upright ambulatory states of the patient; the floating and nonfloating systems behaved differently.
In the uprightposition, the floating systems floated to the top ofthe gastric contents and remained for a longer time, showing prolonged GRT. But the non-floating unitssettled to the lower part of the stomach andunderwent faster emptying as a result of peristaltic contractions and the floating units remained awayfro m the pylorus. However, in supine position, thefloating units are emptied faster than non-floatingunits of similar size.
Concomi tant drug admi nistration
anticholinergics like atropine and propantheline, opiates like codeine and prokinetic agents like metoclopramide and cisapride.
D. Disease states:
Gastric ulcer, diabetes, hypothyroidism increase GRT. Hyperthyroidism, duodenal ulcers decrease GRT.
E. Volume of GI flui d:
The resting volume of the stomach is 25 to 50 ml. When volume is large, the emptying is faster. Flu ids taken at body temperature leave the stomach faster than colder of warmer flu ids.
F. Effect of buoyancy
On comparison of floating and nonfloating units, it wasconcluded that regardless of their sizes the floating units remained buoyant on thegastric contents throughout their residence in the GIT, wh ile the non-floating units sank and remained in the lower part of thestomach. Floating units away from the gastro-duodenal junction were protected fro m theperistaltic waves during digestive phase while then on floating forms stayed close to the pylorus andwere subjected to propelling and retropelling waves of the digestive phase. 25 
TYPES OF DOSAGE FORM FOR GRDDS:
A) FLOATING DRUG DELIV ERY S YSTEMS (FDDS) AND ITS MECHANIS M:
FDDS is one of the important approaches to achieve gastric retention to obtain sufficient drug bioavailability 26 . This system is desirable for drugs with anabsorption window in the stomach or in the uppersmall intestine 27 . This have a less density then gastric fluids and so remain buoyant in thestomach without affecting gastric emptying rate fora pro longed period and the drug is released slowlyas a desired rate fro m the system. After release ofdrug, the residual system is emptied fro m thestomach. This results in an increased GRT and a better control of the fluctuation in plas ma drugconcentration.
The major requirements for FDDS are 28 :
It should release contents slowly to serve as a reservoir. It must maintain specific g ravity lower than gastric contents (1.004 -1.01 g m/cm3). The inherent low density can be provided by theentrapment of air (e.g . hollo w chambers) 29 or bythe incorporation of low density materials (e.g. fattymaterials or oils, or foam powder) [30] [31] [32] . Thesefollowing approaches have been used for the designof floating dosage forms of single and multip le-unitsystems. Recently a single-unit floating system was proposed consisting of polypropylene foam powder, matrix fo rming polymers, drug and filler 33 .
The good floating behaviour of systems could besuccessfully combined with accurate control of theresulting drug release patterns. Single-unit dosageforms are associated with problems such as stickingtogether or being obstructed in the GIT wh ich may produce irritation. On theother hand multip le-unit floating systems may be anattractive alternative since they have been shown to reduce inter and intra-subject availabilit ies indrug absorption as well as to lower the possibility of dose dumping. Various mult iple-unit floatingsystem like air compart ment mult iple-unit system, hollo w microspheres (microballoons) preparedby the emulsion solvent diffusion method 34 , micropart icles based on low density foam powder 31 , beads prepared by emulsion gelatin method 35 etc. can be distributed widely throughout the GIT, providing the possibility of achieving a longerlasting and more reliable release of drugs.Based onthe mechanism of buoyancyFDDS can be div ided as below:
I. Effervescent S ystems
These buoyant systems utilize matrices prepared with swellable poly mers such as methocel, polysaccharides (e.g., ch itosan), effervescentcomponents (e.g., sodium bicarbonate, citric acidor tartaric acid). The system is so prepared thatupon arrival in the stomach, CO 2 isreleased, causing the formu lation to float in thestomach. Other approaches and materials that havebeen reported are a mixtu re of sodium alginate andsodium bicarbonate 17 ,multip le unit floating pills that generate CO 2 when ingested, floating min icapsules witha core of sodium bicarbonate, lactose and poly vinyl pyrrolidone coated with hydro xyl propyl methyl cellulose (HPM C), and floating systemsbased on ion exchange resin technology, etc.
a. Volatile li qui d containing systems -
This type of system consists of two chambers separated by an impermeab le, pressure-responsive, movable bladder.
The first chamber contains the drug and the second chamber contains the volatile liquid. TheGRT of a drug delivery system can be sustained by incorporating an inflatable chamber, which contains a liquid e.g. ether, cyclopentane, that gasifies at body temperature to cause the inflatation of the chamber in the stomach. The device may also consist of a bioerodible plug made up of Poly vinyl alcohol, Po lyethylene, etc. that gradually dissolves causing the inflatable chamber to release gas and collapse after a predetermined time to permit the spontaneous ejection of the inflatable systems fro m the stomach 36 . The device inflates, and the drug iscontinuously released from the reservoir into the gastric flu id. 
b. Gasgenerating systems-
These buoyant delivery systems utilize effervescentreaction between carbonate/bicarbonate salts andcitric/tartaric acid to liberate CO 2 , which getsentrapped in the gellified hydrocollo id layer of thesystems, thus decreasing its specific gravity andmaking it float over chyme 36, 37 . The optimal stoicheometric ratioof cit ric acid and sodium bicarbonate for gasgeneration is reported to be 0.76: 1. A new multip le type of floating dosage system composed of effervescent layers and swellable membrane layers coated on sustained release pills. The inner layer of effervescent agents containing sodium b icarbonate and tartaric acid was divided into two sublayers to avoid direct contact between the two agents. These sublayers were surrounded by a swellable poly mer membrane containing polyvinyl acetate and purified shellac. When this system was immersed in the buffer at 37ºC, it settled down and the solution permeated into the effervescent layer through the outer swellab le membrane. CO 2 was generated by the neutralization reaction between the two effervescent agents, producing swollen pills (like balloons) with a density less than 1.0 g/ ml. It was found that the system had good floating ability independent of pH and viscosity and the drug (Para-amino benzoic acid) released in a sustained manner as shown in Fig.5 37 .
II. Non-Effervescent FDDS
Non-effervescent FDDS are normally prepared fro m gelforming or highly swellable cellulose type hydrocolloids, polysaccharides or matrix fo rming polymers like polyacrylate, polycarbonate, polystyrene and polymethacrylate. In one approach, intimate mixing of drug with a gel forming hydrocolloid wh ich results in contact with gastric flu id after oral ad ministration and maintain a relative integrity of shape and a bulk density less than unity within the gastric environment 38 . The air trapped by the swollen polymer confers buoyancy to these dosage forms. Excip ients used most commonly in these systems includeHPMC polyacry lates, polyvinyl acetate, carbopol, agar, sodium alg inate, calciu m chloride, polyethylene oxide and polycarbonates. This system can be further divided into the sub-types:
a. Hydrodynamically balanced systems OR Colloi dal Gel B arrier System:
Thesesystems contains drug with gel-forming hydrocolloids meant to remain buoyant on the stomach content. This prolongsGRT and maximizes the amount of drug that reaches its absorption sites in the solution form forready absorption.These are single-unit dosageform, containing one or more gel-forminghydrophilic polymers 39 . HPMC, hydroxethyl cellu lose, hydroxypropyl cellu lose, sodiumcarbo xy methyl cellu lose, polycarbophil,polyacrylate, polystyrene, agar, carrageenans oralginic acid are used 40, 41 . The polymer is mixed with drugs and usually administered in HB-capsule. Thecapsule shell dissolves in contact with water andmixture swells to form a gelat inous barrier, whichimparts buoyancy to dosage form in gastric juice fora long period. Because, continuous erosion of the surface allows water penetration to the inner layers maintaining surface hydration and buoyancy to dosage form 41 . Incorporation of fatty excip ients gives low-density formulat ions reducing theerosion. Madopar LP®, based on the system wasmarketed during the 1980"s 43 . Effective drugdeliveries depend on the balance of drug loadingand the effect of poly mer on its release profile.Several strategies have been tried and investigatedto improve efficiencies of the floating hydro dynamically balanced systems 41, 42 .
b. Microporous compartment system
Thistechnology is based on the encapsulation of a drugreservoir inside a microporous compart ment with pores along its top and bottom walls. Theperipheral walls of the drug reservoir compart mentare co mpletely sealed to prevent any direct contactof gastric surface with the undissolved drug. In thestomach, the floatation chamber containingentrapped air causes the delivery system to floatover the gastric content. Gastric flu id entersthrough the aperture dissolves the drug and carriesthe dissolved drug for continuous transport acrossthe intestine for absorption 43 .
c. Alginate beads
Multi-unit floatingdosage forms have been developed from freezedriedcalciu m alg inate. Spherical beads ofapproximately 2.5 mm in dia meter can be preparedby dropping sodium alginate solution into aqueoussolution of © 2011, JDDT. All Rights Reserved ISSN: 2250 -1177 CODEN: JDDTAO calciu m chlo ride, causing theprecipitation of calciu m alginate. The beads arethen separated, snap-frozen in liquid nitrogen, andfreeze-dried at -40ºC for 24 hours, leading to theformat ion of a porous system, which can maintain afloating force for over 12 hours. These floatingbeads gave a prolonged residence time of morethan 5.5 hours. 44
d. Microballoons or Hollow Micros pheres
Microballoons / hollow microspheres loaded withdrugs in their other polymer shelf were prepared bysimp le solvent evaporation or solvent diffusion method to prolong the GRT of the dosage form. 
B. BIO/ MUCO-ADHES IVE S YSTEMS :
Bioadhesive drug delivery systems (BDDS) are used as a delivery device within the lumen toenhance drug absorption in a site specific manner. This approach involves the use of bioadhesive polymers, which can adhere to the epithelial cell surface o r mucin in the stomach. It increases the GRT by increasing the intimacy and duration of contact between the dosage form and the biological membrane. The adherence to the gastric wall increases residence time at a part icular site, thereby improving bioavailab ility 46 . Gastric mucoadhesion does not tend to be strongenough to impart to dosage forms the ability toresist the strong propulsion forces of the stomachwall. The continuous production of mucous by thegastric mucosa to replace the mucous that is lostthrough peristaltic contractions and the dilution ofthe stomach content also seem to limit the potentialof mucoadhesion as a gastroretentive force. Someof the most promising excip ients that have been used are polycarbophil, carbopol, lectins, chitosan andgliadin, etc. BDDS are used as a delivery device within the hu man to enhance drugabsorption in a site-specific manner 47 . The basis of adhesion in that a dosageform can stick to the mucosal surface by different mechanism. These mechanis ms [43, 49 are:
1) The wetting theory, which is basd on the abilityof bioadhesive polymers to spread and developintimate contact with the mucous layers.
2) The diffusion theory which proposes physical entanglement of mucin strands the flexible poly mer chains, or an interpenetration of mucinstrands into the porous structure of the polymersubstrate.
3) The absorption theory, suggests that bioadhesion due to secondary forces such as Vander Waalforces and hydrogen bonding.
4)
The electron theory, which proposes attractiveelectrostatic forces between the glycoprotein mucin network and the bio adhesive material.
Binding of polymers to the mucin/epithelial surface can be divided into three categories:
a. Hydrati onmediated adhesion-Certainhydrophilic polymers have the tendency to imb ibelarge amount of water and become sticky, therebyacquiring b ioadhesive properties. The prolonged gastroretention of the bio/mucoadhesive delivery system is further controlled by the dissolution rateof the polymer. 
C. EXPANDAB LE, UNFOLDAB LE AND SWELLAB LE S YSTEMS
A dosage form in the stomach will withstand gastrictransit if it bigger than pyloric sphincter. However,the dosage form must be small enough to beswallowed, and must not cause gastric obstructioneither singly or by accumulation. Thus, theirconfigurations 52, 53 are required to develop anexpandable system to prolong GRT: 1) A s mall configuration for oral intake, 2) An expanded gastroretentive form, and 3) A final s mall form enabling evacuation followingdrug release fro m the device.
Thus, gastro-retention is improved by thecombination of substantial dimension with highrigidity of dosage form to withstand peristalsis andmechanical contractility of the stomach. They are available indifferent geometric forms like tetrahedron, ring orplanner membrane (4 -label disc or 4limbed crossform) of bioerodible poly mer co mpressed withinacapsule which extends in the stomach 54, 55 . Swellab le systems are also retained in the GIT due to their mechanicalproperties. The swelling is usually results from osmotic absorption of water. Expandable systems have somedrawbacks like problematical storage of mucheasily hydrolysable, biodegradable polymersrelatively short-lived mechanical shape memory forthe unfolding system most difficult to industrialize and not cost effective. Again, permanent retentionof rigid, large single-unit expandable drug deliverydosage forms may cause brief obstruction, intestinaladhesion and gastropathy.
D. HIGH DENS ITY S YSTEMS -
Gastric contents have a density close to water (1.004 g/cm 3 ). When high density pellets is given to the patient, it will sink to the bottom of the stomach and are entrapped in the folds of the antrum and withstand the peristaltic waves of the stomach wall. Sedimentation has been emp loyed as a retentionmechanism for pellets that are small enough to beretained in the rugae or folds of the stomach body near the pyloric region, which is the part of theorgan with the lowest position in an uprightposture. Dense pellets (approximately 3g/cm 3 ) trapped in rugae also tend to withstand theperistaltic movements of the stomach wall. Withpellets, the GI transit time can be extended fro m anaverage of 5.8-25 hours, depending more ondensity than on the diameter of the pellets27.Co mmonly used excip ients are barium sulphate,zinc o xide, titaniu m dio xide and iron powder, etc.These materials increase density by up to 1.5-2.4g/cm 3 . The only majo r drawbacks with this systems is that it is technically d ifficult to manufacture them with a large amount of drug (>50%) and to achieve the required density of 2.4-2.8 g/cm 3
E. MAGNETIC S YS TEMS
This approach toenhance the GRT is basedon the simple principle that the dosage formcontains a small internal magnet, and a magnetplaced on the abdomen over the position of thestomach. Although magnetic system seems towork, the external magnet must be positioned with adegree of precision that might co mpro misepatient compliance.The technological approach in rabbits with bioadhesive granules containing ultra-fine ferrite. They guided them to oesophagus with an external magnet for the initial 2 minutes and almost all the granules were retained in the region after 2hours 56 .
F. RAFT FORMING S YSTEM
Raft System incorporate alg inate gels these have a carbonate component and, upon reaction with gastric acid, bubbles form in the gel, enabling floating 57 . Raft forming systems have received much attention for the drug delivery for GI infections and disorders. Themechanism includes the formation ofviscous cohesive gel in contact with gastric fluids, wherein eachportion of the liquid swells forming a continuous layer called a raft.Th is raft floats on gastric fluids because of low bulk density createdby the formation of CO 2 . Usually, the system ingredients includes agel forming agent and alkaline bicarbonates or carbonatesresponsible for the format ion of CO 2 to make the system less denseand float on the gastric flu ids An antacid raft forming floating system contains a gel forming agent (e.g. sodium alginate), sodiu mbicarbonate and acid neutralizer, which forms a foaming sodiumalginate gel (raft), which when comes in contact with gastric flu ids,the raft floats on the gastric flu ids and prevents the reflu x of thegastric contents (i.e. gastric acid) into the esophagus by acting as abarrier between the stomach and esophagus 58 .
G. SUPER POROUS HYDROGEL S YS TEMS
These swellab le systems differ sufficiently fro m theconventional types to warrant separateclassification. Super porous hydrogel that expand dramat ically (hundreds of times their dehydrated form within a matter of seconds) when immersed in water. With pore size ranging, 10n m to 10µm, absorption window by conventional hydrogel is a very slow process and several hours may be needed to reach an equilibriu m state during which parameter evacuation of the dosage form may occur 59 . In this approach to improve GRT super porous hydrogel of average pore size less than 100µm, swell toequilibriu m size within a minute due to rapid wateruptake by capillary wetting through numerousinterconnected open pores 60 . They swell to a largesize (swelling ratio : 100 or mo re) and are intendedto have sufficient mechanical strength to withstandpressure by gastric contraction. This is advised byco-formu lation of hydrophilic particu late material 61 .
H. SWELLING S YSTEMS
These are the dosage forms, which after swallowing; swell at an extent that prevents their exit fro m the pylorus. As a result, the dosage form is retained in the stomach for a long period of time. These systems may be named as "plug type systems", since they exhib it the tendency to remain lodged at the pyloric sphincter. The formu lation is designed for gastric retention and controlled delivery of the drug into the gastric cavity. Such poly meric matrices remain in the gastric cavity for several hours even in the fed state. Sustained and controlled drug release may be achieved by selection of proper molecular weight polymer, and swelling of the poly mer retards the drug release. On coming in contact with gastric fluid, the polymer imb ibes water and swells. The extensive of these polymers is due to the presence of physical/chemical cross -links in the hydrophilic poly mer network. 
ADVANTAGES OF GAS TRORET ENTIVE DRUG DELIVERY S YS TEMS
1) The bioavailability of therapeutic agents can be significantly enhanced especially for those which get metabolized in the upper GIT by thisGRDDS in comparison to the admin istration of non-GRDDS 62 .There are several different factors related to absorption and transit of the drug in the GIT that act concomitantly to influence the magnitude of drug absorption 63 . 2) In a similar fashion to the increased efficacy of active transporters exhibit ing capacity limited activity, the pre-systemic metabolis m of the tested compound may be considerably increased when the drug is presented to the metabolic enzy mes (cytochrome P450, in particular CYP3A 4) in a sustained manner, rather than by a bolus input. 3) For drugs with relatively short half life, sustained release may result in a flip-flop pharmacokinetics and also enable reduced frequency of dosing with improved patientcompliance. 4) They also have an advantage over their conventional system as it can be used to overcome the adversities of the GRT as well as the GET. As these systems are expected to remain buoyant on the gastric fluid without affecting the intrinsic rate of emp loying because of low density. 5) GRDDS can produce prolong and sustain release of drugs from dosage forms which avail local therapy in the stomach and small intestine. Hence they are useful in the treatment of disorders related to stomach and small intestine. 6) The controlled, slow delivery of drug form GRDF provides sufficient local action at the diseased site, thus minimizing or eliminating systemic exposure of drugs. This site-specific drug delivery reduces undesirable effects of side effects. 7) Continuous input of the drug following CR-GRDF administration produces blood drug concentrations within a narrower range compared to the IR dosage forms. Thus, GRDF min imize the fluctuation of drug concentrations and effects.Therefore, concentration dependent adverse effects that are associated with peak concentrations can be presented. This feature is of special importance for drug with a narrow therapeutic index 64 . 8) Retention of the drug in the GRDF at the stomach minimizes the amount of drug that reaches the colon. Thus, undesirable activities of the drug in colon may be prevented. 9) In many cases, the pharmacological response which intervenes with the natural physiologic processes provokes a rebound activity of the body that minimizes drug activity. Thus Slow input of the drug into the body was shown that gastroretentive drug delivery system can minimize the counter activity of the body leading to higher drug efficiency. 10) Reduction of fluctuation in drug concentration makes it possible to obtain improved selectivity in receptor activation. 11) The sustained mode of drug release from gastroretentive dosage form enables extension of the time over a critical concentration and thus enhances the pharmacological effects and improves the chemical outcomes.
LIMITATIONS OF GASTRORET ENTIVE DRUG DELIVERY S YS TEMS
GRDDS have potential in imp roving BA of drugsexhibiting "absorption window". Ho wever theyhave certain limitations. One of the majordisadvantages of the © 2011, JDDT. All Rights Reserved ISSN: 2250 -1177 CODEN: JDDTAO floating system is therequirement of h igh levels of fluids in the stomachfor the delivery system to float and work efficiently. 65 1) Require a higher level o f fluids in the stomach.
2) Not suitable for drugs that may cause gastric lesions e.g. Non-steroidal anti inflammatory drugs. Drugs that are unstable in the strong acidic environment, these systems do not offer significant advantages over the conventional dosage forms fo r drugs that are absorbed throughout the GIT. 3) Drugs intended for selective release in the colon E.g. 5-amino salicylic acid and cort icosteroids etc. 4) The floating systems in patients with achlorhydria can be questionable in case of swellab le system. 5) Retention of high density systems in the antrum part under the migrating waves of the stomach is questionable. 6) The mucus on the walls of the stomach is in a state of constant renewal, resulting in unpredictable adherence. 7) Bioadhesion in the acidic environment and high turnover of mucus may raise questions about the effectiveness of this technique. Similarly retention of high density systems in the antrum part under the migrat ing waves of the stomach is questionable. 8) In all the above systems the physical integrity of the system is very impo rtant and primary requirement.
9) The residence time in the stomach depends upon the digestive state. Hence FDDS should be administered after the meal. [4 10) The ability to float relies on the hydration state of the dosage form, In order to keep these tablets floating in vivo, intermittent admin istration of water (a tumbler full, every 2 hours) is beneficial. 4 11) The ability of the drug to remain in the stomach depends upon the subject being positioned upright. 66 12) Nifedipin like drug can"t be candidate for FDDS since the slow gastric emptying may lead to the reduced systemic bio -availab ility. 67 
CONCLUS IONS:
Controlled release gastroretentive dosage forms (CR-GRDF) enable prolonged and continuous input of the drug to the upper parts of the gastrointestinal (GI) tract and improve the bioavailability of medicat ions that are characterized by a narrow absorption window. Based on the literature surveyed, it may be concluded that gastroretentive drug delivery offers various potential advantages for drug with poor bioavailability due their absorption is restricted to the upper gastrointestinal tract (GIT) and they can be delivered efficiently thereby maximizing their absorption and enhancing absolute bioavailability. And hence, it can be concluded that these dosage forms serve the best in the treatment of diseases related to the GIT and for extracting a prolonged action fro m a drug with a short half-life.
FUTUR E POTENTIAL FOR GRDDS:
While the control of drug release profiles has been a major aim o f pharmaceutical research and development in the past two decades, the control of GI transit profiles could be the focus of the next two decades and might result in the availability of new products with new therapeutic possibilit ies and substantial benefits for patients. Soon, the so-called "once-a-day" formulat ions may be rep laced by novel gastroretentive products with release and absorption phases of approximately 24 hours.
